Liu P, Xu S, Zhang M, et al. Anticancer activity in human multiple myeloma U266 cells: synergy between cryptotanshinone and arsenic trioxide [J]. Metallomics, 2013, 5(7):871.
Hamada A, Miyano H, Watanabe H, et al. Interaction of imatinib mesilate with human P-glycoprotein[J]. J Pharmacol Exp Ther, 2003, 307(2):824.
[6]
Radujkovic A, Schad M, Topaly J, et al. Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL-inhibition of P-glycoprotein function by 17-AAG [J]. Leukemia, 2005, 19(7):1198.
Hu T, To K K, Wang L, et al. Reversal of P-glycoprotein (P-gp) mediated multidrug resistance in colon cancer cells by cryptotanshinone and dihydrotanshinone of Salvia miltiorrhiza[J]. Phytomedicine, 2014, 21(11):1264.
[11]
Strout M P, Schatz D G. Imatinib resistance and progression of CML to blast crisis: somatic hypermutation AIDing the way [J]. Cancer Cell, 2009, 16(3):174.
[12]
Mahon F X, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial [J]. Lancet Oncol, 2010, 11(11):1029.
Lu L, Li C, Li D, et al. Cryptotanshinone inhibits human glioma cell proliferation by suppressing STAT3 signaling [J]. Mol Cell Biochem, 2013, 381(1/2):273.
[16]
Shin D S, Kim H N, Shin K D, et al. Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells [J]. Cancer Res, 2009, 69(1):193.
[17]
Sayed D, Badrawy H, Gaber N, et al. p-Stat3 and bcr/abl gene expression in chronic myeloid leukemia and their relation to imatinib therapy [J]. Leuk Res, 2014, 38(2):243.
[18]
Kantarjian H, O\'Brien S, Jabbour E, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience [J]. Blood, 2012, 119(9):1981.
[19]
Warsch W, Kollmann K, Eckelhart E, et al. High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia [J]. Blood, 2011, 117(12):3409.
Ge Y, Cheng R, Zhou Y, et al. Cryptotanshinone induces cell cycle arrest and apoptosis of multidrug resistant human chronic myeloid leukemia cells by inhibiting the activity of eukaryotic initiation factor 4E[J]. Mol Cell Biochem, 2012, 368(1/2):17.
[22]
Ge Y, Yang B, Xu X, et al. Cryptotanshinone acts synergistically with imatinib to induce apoptosis of human chronic myeloid leukemia cells [J]. Leuk Lymphoma, 2015, 56(3):730.
[23]
Widmer N, Rumpold H, Untergasser G, et al. Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels [J]. Leukemia, 2007, 21(7):1561.
Jung J H, Kwon T R, Jeong S J, et al. Apoptosis induced by tanshinone ⅡA and cryptotanshinone is mediated by distinct JAK/STAT3/5 and SHP1/2 signaling in chronic myeloid leukemia K562 cells [J]. Evid Based Complement Alternat Med, 2013, doi:10.1155/2013/805639.
[28]
Kim J H, Jeong S J, Kwon T R, et al. Cryptotanshinone enhances TNF-alpha-induced apoptosis in chronic myeloid leukemia KBM-5 cells [J]. Apoptosis, 2011, 16(7):696.
